Ac-SDKP
Ac-SDKP
Also known as: Thymosin Beta-4 Fragment Ac-SDKP, Goralatide, Seraspenide
Overview
Key Facts
Primary Goal: A tetrapeptide naturally released from Thymosin Beta-4 by prolyl oligopeptidase
A tetrapeptide naturally released from Thymosin Beta-4 by prolyl oligopeptidase. Acts as a potent endogenous antifibrotic agent and is normally present in human plasma and urine. Hydrolyzed by ACE. Half-Life ~5 minutes (rapidly cleaved by ACE) Typical Dose 100–400 mcg Frequency 1x daily Cycle Length 4-8 weeks
Dosing Information
Half-Life
~5 minutes (rapidly cleaved by ACE)
Typical Dose
100–400 mcg
Frequency
1x daily
Cycle Length
4-8 weeks
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Studied extensively in animal models of cardiac, renal, and hepatic fibrosis with consistent antifibrotic results. Its role as the endogenous substrate of ACE partly explains the antifibrotic benefits of ACE inhibitors. Phase 1 human data exists from hematopoietic studies (Goralatide/Seraspenide).
Frequently Asked Questions
Common questions about Ac-SDKP
UK-Specific Information
Exclusive data points and guidance for UK residents using Ac-SDKP
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
AOD-9604
Research and therapeutic applications of AOD-9604
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.